Overview

Hypoxic Pulmonary Vasoconstriction Pilot Study

Status:
Completed
Trial end date:
2014-01-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the events leading to smoking-associated centrilobular and paraseptal emphysema are caused by a failure of the lungs' inherent mechanisms to block hypoxic pulmonary vasoconstriction (HPV) in areas of smoking-induced inflammation.
Phase:
Phase 4
Details
Lead Sponsor:
Eric A. Hoffman
University of Iowa
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)
Treatments:
Sildenafil Citrate